Out of 400 Drugs, Only These Might Help You Live Longer - Dr. Kevin Perez and Siim Land

Key Takeaways

• Statins, PDE5 inhibitors, SGLT2 inhibitors, and estrogen therapies linked to lower mortality
• Metformin showed no significant lifespan benefit in the UK Biobank analysis
• Observational design limits causal inference despite extensive confounder adjustment
• Hormone and vascular drugs may act through insulin sensitivity and cardiovascular health
• Ongoing animal studies aim to validate human longevity signals across species

Pulse Analysis

The recent UK Biobank analysis examined medication records for over half a million participants across two decades, comparing each drug’s users with rigorously matched controls. By adjusting for age, sex, BMI, smoking status, socioeconomic factors and disease burden, the researchers sought a real‑world signal of reduced all‑cause mortality—a proxy for extended lifespan. Out of more than 400 pharmaceutical agents, only fourteen emerged with statistically robust associations, underscoring how rare genuine longevity signals are when confounding by indication is stripped away.

The shortlist is dominated by four therapeutic families: statins, PDE5 inhibitors such as sildenafil, SGLT2 inhibitors for diabetes, and estrogen‑based hormone replacement. These drugs converge on pathways that improve vascular function, insulin sensitivity, and hormonal balance, all of which have been linked to slower biological aging. Notably, metformin—a staple of longevity discourse—failed to demonstrate a mortality advantage in this cohort, highlighting the gap between experimental promise and population‑level outcomes. The findings suggest that direct modulation of cardiovascular and metabolic health may be more impactful than broad‑spectrum metabolic agents.

While the observational nature of the study precludes definitive causality, the results provide a prioritized agenda for translational research. Ongoing experiments in worms, flies, fish and mice are testing whether the same drugs extend lifespan across species, which could illuminate conserved mechanisms such as PI3K‑mTOR signaling. Clinicians may also reconsider off‑label prescribing of these agents for longevity, balancing proven disease benefits against the modest mortality signal. Ultimately, integrating drug‑based interventions with emerging biomarkers like GDF‑15 could refine personalized strategies to delay aging‑related decline.